ArticleAdvanced healthcare materials2017
Toward a Single-Dose Vaccination Strategy with Self-Encapsulating PLGA Microspheres.
Article in Advanced healthcare materials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 42 citations in OpenAlex.
- Atomic layer deposition for core-shell microparticle vaccines enabling programmable antigen delivery to lymph nodes enhance humoral immune responses.bioRxiv : the preprint server for biology · 2026Article
- Nanoscale Biodegradable Printing for Designed Tuneability of Vaccine Delivery Kinetics.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Immune Potentiation of PLGA Controlled-Release Vaccines for Improved Immunological Outcomes.ACS omega · 2024Article
- Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects.International journal of nanomedicine · 2024Review
- Metal-HisTag coordination for remote loading of very small quantities of biomacromolecules into PLGA microspheres.Bioengineering & translational medicine · 2022Article
- Emerging vaccine nanotechnology: From defense against infection to sniping cancer.Acta pharmaceutica Sinica. B · 2022Review
- Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health.Nature nanotechnology · 2021Review
- Microarray patches enable the development of skin-targeted vaccines against COVID-19.Advanced drug delivery reviews · 2021Review
- Engineered drug delivery devices to address Global Health challenges.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- Protein Loading into Spongelike PLGA Microspheres.Pharmaceutics · 2021Article
- Hitchhiking on Controlled-Release Drug Delivery Systems: Opportunities and Challenges for Cancer Vaccines.Frontiers in pharmacology · 2021Review
- Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.ACS biomaterials science & engineering · 2020Review
- Improving Vaccine and Immunotherapy Design Using Biomaterials.Trends in immunology · 2018Review
- Self-encapsulating Poly(lactic-co-glycolic acid) (PLGA) Microspheres for Intranasal Vaccine Delivery.Molecular pharmaceutics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Poly(lactic-co-glycolic acid) (PLGA) microspheres have been widely examined for vaccine applications due to their attractive features of biocompatibility, biodegradability, ability to be internalized by antigen-presenting cells, and long-term antigen release. However, one of the major challenges for PLGA particle vaccines is the potential for antigen instability and loss of antigenicity and immunogenicity. To address this challenge, we have developed a new method of "self-healing" encapsulation in PLGA microspheres, where pre-made PLGA microspheres are loaded with protein antigens under aqueous conditions with minimal impact on their antigenicity and immunogenicity. In this report, we show that mice immunized with self-encapsulating PLGA microspheres in a prime-boost regimen generated significantly enhanced antigen-specific CD8α+ T cell and antibody responses, compared with mice immunized with free, soluble protein admixed with calcium phosphate gel, a widely used adjuvant. Furthermore, a single-dose of microspheres designed for >40 day sustained antigen release elicited robust cellular and humoral immune responses as efficiently as the prime-boost vaccinations with calcium phosphate gel. Overall, these results suggest excellent potential of our self-encapsulating PLGA microspheres as a vaccine platform for multiple-dose as well as single-dose vaccinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.